The article summerizes published data on skin involvement in COVID-19 infection, adresses immunosupressive management issue in patients with dermatological, rheumatologic and inflammatory bowel diseases in the COVID-19 era as well as published data on skin effects of introduced antiviral COVID-19 infection therapy.